CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 304 enrolled
Drug / intervention
Roflumilast foam 0.3% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04128007
NCT04128007Phase 2Completed
CompareCT.gov

A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults With Scalp and Body Psoriasis

Arcutis Biotherapeutics, Inc.·interventional·Posted Oct 16, 2019·Updated Oct 26, 2022

In Brief

A Phase 2 clinical trial evaluating Roflumilast foam 0.3% and Vehicle foam for Plaque Psoriasis. Completed, enrolled 304 participants across 47 sites in 4 countries.

Detailed Summary

This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesAustralia, Bulgaria, Canada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 16, 2019
Enrollment StartJan 13, 2020
Primary CompletionSep 23, 2020
Study CompletionSep 25, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.7 years ago

Interventions

Roflumilast foam 0.3%drug

experimental

Vehicle foamdrug

experimental